Shide Kotaro
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki.
Rinsho Ketsueki. 2018;59(10):2075-2083. doi: 10.11406/rinketsu.59.2075.
One of the main molecular features of myeloproliferative neoplasms (MPNs) is the high frequency of JAK2V617F or CALRexon 9 mutations. The mouse models driven by these mutations suggest that they are the direct cause of MPNs and that the expression levels of mutated genes define the disease phenotype. The function of MPN-initiating cells was also elucidated using these mouse models. Furthermore, these mouse models play important roles as disease models to investigate the effects and mechanisms of action of therapeutic drugs such as JAK2 inhibitors and interferon α against MPNs. The mutation landscape of hematological tumors has already been clarified using next-generation sequencing technology, and future research on the importance of the functional analysis of mutant genes in vivo should be emphasized. Thus, it is necessary to promote rapid genetic modification techniques such as genome editing.
骨髓增殖性肿瘤(MPN)的主要分子特征之一是JAK2V617F或CALR外显子9突变的高频率。由这些突变驱动的小鼠模型表明,它们是MPN的直接病因,且突变基因的表达水平决定疾病表型。利用这些小鼠模型也阐明了MPN起始细胞的功能。此外,这些小鼠模型作为疾病模型,在研究JAK2抑制剂和干扰素α等治疗药物对MPN的作用效果及作用机制方面发挥着重要作用。利用下一代测序技术已经明确了血液肿瘤的突变图谱,未来应强调对体内突变基因功能分析重要性的研究。因此,有必要推广如基因组编辑等快速基因改造技术。